<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="style.css">
        <title> Omnibuster Section </title>
    </head>

    <body>
        <div class="section">
            <h1> Section s3101 </h1>
            <p> <section id="d3355e13068" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101" style="-uslm-lc:I650144"><num value="3101">SEC. 3101. </num><heading>NATIONAL ACADEMIES REPORT ON AMERICA’S MEDICAL PRODUCT SUPPLY CHAIN SECURITY.</heading><subsection class="indent0 fontsize10" id="d3355e13073" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/a" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">(a) </num><heading><inline class="small-caps">In General</inline>.—</heading><content>Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the “National Academies”) to examine, and, in a manner that does not compromise national security, report on, the security of the United States medical product supply chain.</content>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13084" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">(b) </num><heading><inline class="small-caps">Purposes</inline>.—</heading><chapeau>The report developed under this section shall—</chapeau><paragraph class="indent1 fontsize10" id="d3355e13093" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><chapeau>assess and evaluate the dependence of the United States, including the private commercial sector, States, and the Federal Government, on critical drugs and devices that are sourced or manufactured outside of the United States, which may include an analysis of—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e13098" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/1/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>the supply chain of critical drugs and devices of greatest priority to providing health care;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13105" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/1/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><content>any potential public health security or national security risks associated with reliance on critical drugs and devices sourced or manufactured outside of the United States, which may include responses to previous or existing shortages or public health emergencies, such as infectious disease outbreaks, bioterror attacks, and other public health threats;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13112" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/1/C" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">(C) </num><content>any existing supply chain information gaps, as applicable; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13119" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/1/D" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">(D) </num><content>potential economic impact of increased domestic manufacturing; and</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e13127" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>provide recommendations, which may include a plan to improve the resiliency of the supply chain for critical drugs and devices as described in paragraph (1), and to address any supply vulnerabilities or potential disruptions of such products that would significantly affect or pose a threat to public health security or national security, as appropriate, which may include strategies to—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e13132" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/2/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>promote supply chain redundancy and contingency planning;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13139" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/2/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><content>encourage domestic manufacturing, including consideration of economic impacts, if any;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13146" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/2/C" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">(C) </num><content>improve supply chain information gaps;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13153" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/2/D" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">(D) </num><content>improve planning considerations for medical product supply chain capacity during public health emergencies; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13160" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/b/2/E" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">(E) </num><content>promote the accessibility of such drugs and devices.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13169" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/c" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">(c) </num><heading><inline class="small-caps">Input</inline>.—</heading><chapeau>In conducting the study and developing the report under subsection (b), the National Academies shall—</chapeau><paragraph class="indent1 fontsize10" id="d3355e13178" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/c/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><content>consider input from the Department of Health and Human Services, the Department of Homeland Security, the Department of Defense, the Department of Commerce, the Department of State, the Department of Veterans Affairs, the Department of Justice, and any other Federal agencies as appropriate; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e13185" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/c/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><content>consult with relevant stakeholders, which may include conducting public meetings and other forms of engagement, as appropriate, with health care providers, medical professional societies, State-based societies, public health experts, State and local public health departments, State medical boards, patient groups, medical product manufacturers, health care distributors, wholesalers and group purchasing organizations, pharmacists, and other entities with experience in health care and public health, as appropriate.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13193" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptA/s3101/d" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">(d) </num><heading><inline class="small-caps">Definitions</inline>.—</heading><content>In this section, the terms “device” and “drug” have the meanings given such terms in section 201 of the Federal Food, Drug, and Cosmetic Act (<ref href="/us/usc/t21/s321">21 U.S.C. 321</ref>).</content>
</subsection>
</section></p>
        </div>  
    </body>